康华生物：8月22日召开董事会会议

Group 1 - The core viewpoint of the article is that Kanghua Biological announced the convening of its third board meeting to review the semi-annual report for 2025, indicating ongoing corporate governance and financial transparency [1] - For the fiscal year 2024, Kanghua Biological's revenue composition shows that non-immunization planning vaccines account for 92.59% of total revenue, highlighting the company's focus on this segment [1] - As of the report, Kanghua Biological has a market capitalization of 11.1 billion yuan, reflecting its valuation in the market [1]